Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Receivables - Other (2018 - 2025)

Historic Receivables - Other for Takeda Pharmaceutical (TAK) over the last 8 years, with Q1 2025 value amounting to $380.5 million.

  • Takeda Pharmaceutical's Receivables - Other rose 75.75% to $380.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $380.5 million, marking a year-over-year increase of 75.75%. This contributed to the annual value of $381.1 million for FY2025, which is 179.65% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Receivables - Other of $380.5 million as of Q1 2025, which was up 75.75% from $377.6 million recorded in Q1 2024.
  • Takeda Pharmaceutical's Receivables - Other's 5-year high stood at $714.3 million during Q1 2021, with a 5-year trough of $377.6 million in Q1 2024.
  • Its 5-year average for Receivables - Other is $542.5 million, with a median of $559.4 million in 2023.
  • In the last 5 years, Takeda Pharmaceutical's Receivables - Other plummeted by 3249.65% in 2024 and then surged by 75.75% in 2025.
  • Takeda Pharmaceutical's Receivables - Other (Quarter) stood at $714.3 million in 2021, then fell by 4.68% to $680.9 million in 2022, then fell by 17.84% to $559.4 million in 2023, then crashed by 32.5% to $377.6 million in 2024, then grew by 0.76% to $380.5 million in 2025.
  • Its Receivables - Other was $380.5 million in Q1 2025, compared to $377.6 million in Q1 2024 and $559.4 million in Q1 2023.